RxDoctor Payments Data

Abra Woolard, APRN

Family · St Joseph, MONPI 1194067991

Payments from drug & device makers

$7,608in general payments, 2019–2025

Across 437 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • EMD Serono, Inc.$681
  • UCB, Inc.$599
  • Novartis$364
  • Medtronic$320
  • Biogen$271
  • plus $4K from 43 others

What the payments were for

  • Speaking & faculty fees$280%
  • Food & beverage$7,580100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,608 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$81,571
Medicare patients
508
Services billed
1,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5048$344,109
Austedo XrDeutetrabenazine17$236,455
Gamunex-CImmune Globul G/Gly/Iga Avg 4649$118,896
NuplazidPimavanserin Tartrate19$93,124
AmpyraDalfampridine13$55,370
Aimovig AutoinjectorErenumab-Aooe32$34,873
Nurtec OdtRimegepant Sulfate26$32,803
Emgality PenGalcanezumab-Gnlm32$24,180
QuliptaAtogepant17$21,293
NuedextaDextromethorphan Hbr/Quinidine27$19,799
Levetiracetam391$12,469
Ajovy AutoinjectorFremanezumab-Vfrm12$10,012
Entacapone81$8,585
Carbidopa-LevodopaCarbidopa/Levodopa298$7,808
Carbamazepine ErCarbamazepine38$7,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$254$236,45517 claims
Grifols USA, LLCGamunex-C$39$118,89649 claims
Acadia Pharmaceuticals IncNuplazid$114$93,12419 claims
Acorda Therapeutics, IncAmpyra$28$55,37013 claims
PfizerNurtec Odt$185$32,80326 claims
AbbVieQulipta$1,492$21,29317 claims
Upsher-smith Laboratories LLCTopiramate$34$4,509404 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in St Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →